Guardant Health, Inc. announced the first clinical readout from its collaboration in the RADIOHEAD study with the Parker Institute for Cancer Immunotherapy (PICI). Data published in Cancer Research Communications validated Guardant Reveal's ability to detect responses to immunotherapy across multiple solid tumor types in advanced-stage cancer patients.
The study found that Guardant Reveal identified non-responders more than three months, and in some cases nearly five months, before disease progression was visible by standard methods. This earlier detection provides crucial insights for oncologists to make timely treatment decisions.
Craig Eagle, M.D., Chief Medical Officer at Guardant Health, stated that precise serial monitoring at the molecular level offers real value to oncologists and patients using immunotherapy. This study shows Guardant Reveal's potential to revolutionize how oncologists assess patient response, improving patient outcomes and quality of care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.